Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. cut its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,370,855 shares of the company’s stock after selling 695,467 shares during the period. Meitav Investment House Ltd. owned 0.67% of Cellebrite DI worth $30,200,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its holdings in shares of Cellebrite DI by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock worth $7,202,000 after buying an additional 75,092 shares during the last quarter. Telemark Asset Management LLC purchased a new position in Cellebrite DI in the 3rd quarter worth $6,736,000. Two Sigma Advisers LP lifted its position in Cellebrite DI by 9.8% during the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock worth $22,584,000 after acquiring an additional 120,000 shares during the period. Harbor Capital Advisors Inc. grew its stake in Cellebrite DI by 65.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after purchasing an additional 62,320 shares during the last quarter. Finally, State Street Corp grew its stake in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after purchasing an additional 30,052 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CLBT shares. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Craig Hallum upped their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Trading Down 3.1 %

Shares of NASDAQ CLBT opened at $19.66 on Thursday. Cellebrite DI Ltd. has a 52 week low of $10.24 and a 52 week high of $26.30. The firm has a 50-day simple moving average of $22.57 and a 200-day simple moving average of $19.33.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.